Amgen's Prolia Gains First Regulatory Win: Market Approval in Europe
This article was originally published in The Pink Sheet Daily
Executive Summary
Amgen and GlaxoSmithKline will assume marketing responsibilities in Europe for osteoporosis, and Amgen will market it for oncology.
You may also be interested in...
Amgen's Prolia Bags Favorable Draft Appraisal From UK Medicines Watchdog
NICE considers denosumab a cost-effective use of NHS resources for second-line osteoporosis use.
Amgen's Prolia Bags Favorable Draft Appraisal From UK Medicines Watchdog
NICE considers denosumab a cost-effective use of NHS resources for second-line osteoporosis use.
Aranesp Sales Continue To Slide But Amgen Reports A Solid Year
During its fourth-quarter 2009 earnings call, Amgen also reported it has re-filed denosumab for osteoporosis with FDA.